Diagnostic Partners:
Enhancing ctDNA with CTC-DNA
Rarecells is leading the evolution of powerful, multi-analyte liquid biopsy diagnostics. The ISET® platform complements and strengthens ctDNA testing by adding intact circulating tumor cells DNA (CTC-DNA) to reveal a more complete tumor profile. It also can integrate genomic, phenotypic, and morphological data in one test delivering earlier and more comprehensive information.
Why Combine CTC-DNA and ctDNA?
- Detect Cancer Earlier
CTC-DNA can appear before ctDNA is shed, enabling earlier detecton in early-stage disease. - Enrich Tumor Profiling
Combine DNA, protein expression, morphology, and other cellular biomarkers for deeper tumor characterization. - Broaden Genomic Coverage:
Capture rare and subclonal variants often missed by ctDNA-only approaches. - Guide Therapy Decisions
Monitor genotypic resistance and recurrence (MRD) earlier to optimize patient management.
The ISET® Platform Advantage
- Compatible with stabilized blood samples for operatonal flexibility
- Enables dual extraction of ctDNA and CTC-DNA from the same blood draw
- Marker-independent capture of heterogeneous CTCs across all tumor types.
- Clinically validated in multiple solid cancers with proven diagnostic utility
Partner with Rarecells to build the next generation of comprehensive cancer diagnostics.
Contact Us: contact@rarecells.com
Contact Us: contact@rarecells.com